NGM Bio Presents Comprehensive Findings from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in Oral Plenary Presentation at The Digital International Liver Congress™ (ILC) 2020 and Announces Enrollment Completed in Phase 2b ALPINE 2/3 Study

NEXT STORY
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
PREV STORY
Kiadis announces new data demonstrating FC21-NK cells were well tolerated and showed encouraging signs of antitumor and suspected antimicrobial activity in 13 patients with relapsed/refractory acute myeloid leukemia (R/R AML)
Subscribe to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children

Tasigna is the first and only second-generation tyrosine kinase inhibitor approved in the EU ...

author_avatar
NASDAQ Market News

Chiasma Announces Three Poster Presentations at ENDO 2019

author_avatar
NASDAQ Market News

Zai Lab Announces Upcoming Presentations at December Investor Conferences

author_avatar
NASDAQ Market News